Multi-Omics discovery and clinical validation of IGFBP2, B2M, and CST3 as a serum biomarker panel for diabetic kidney disease progression
Through a multi-omics approach, we identified IGFBP2/B2M/CST3 as a non-invasive biomarker panel for DKD progression, highlighting their roles as both diagnostic markers and therapeutic targets.
Authors
- Lingling Wei (ORCID: https://orcid.org/0000-0003-2857-6944)
- Jianbo Wu (ORCID: https://orcid.org/0000-0002-3574-5585)
- Shuwen Zheng
- Yan Wang (ORCID: https://orcid.org/0000-0003-2820-8391)
- Longyan Yang (ORCID: https://orcid.org/0000-0002-0815-5627)
- Ruili Yin (ORCID: https://orcid.org/0000-0002-1932-1619)
- Hongling Zhao
- Lijie Zhang (ORCID: https://orcid.org/0000-0002-9435-9799)
- Kun Li (ORCID: https://orcid.org/0000-0002-2026-9969)
- Yongsong Xu
- Yin Tong (ORCID: https://orcid.org/0000-0001-7551-5509)
- Zhiguo Zhang (ORCID: https://orcid.org/0000-0002-0810-5320)
- Elsayed Metwally
Institutions
- Suez Canal University (EG)
- Yunnan University (CN)
- Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
Publication Details
- Journal
- Gene
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.gene.2025.149858
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00